王前奔，男，博士生导师，中国医学科学院基础医学研究所/北京协和医学院基础学院长聘教授。2002年获美国马里兰大学巴尔的摩分校博士学位，2003–2008年在哈佛大学Dana-Farber肿瘤研究所从事博士后研究，并任哈佛大学医学院讲师。此后历任美国俄亥俄州立大学医学院分子和细胞生物化学系助理教授（预备终身教职）、分子和细胞生物化学系及肿瘤生物学与遗传学系副教授（终身教职），以及杜克大学医学院病理学系终身正教授和冠名讲席教授。2025年8月全职回国，加入中国医学科学院基础医学研究所/北京协和医学院基础学院。
长期从事疾病相关的基因调控机制与RNA靶向基因治疗研究，在激素依赖性肿瘤转录与表观遗传调控领域取得系统性成果。近年来，将CRISPR/Cas13 RNA编辑与脂质纳米药物精准递送结合，建立“RNA精准治疗平台”，在癌症转移、耐药、免疫逃逸及冠状病毒感染及感染后肺修复等方面取得突破。相关成果发表于Cell、Molecular Cell、Nature Genetics、Nature Chemical Biology、Cell Research、PNAS、Nature Communications、EMBO Journal、Cancer Research、Advanced Science、Nano Research等国际期刊。
现任美国基础泌尿学研究学会（SBUR）常务董事、执行委员会委员，并担任2025年第33届年会主席。曾任美国国立卫生研究院（NIH）肿瘤基因调控学科评审组常任委员，杜克大学医学院临床科学终身教授评审委员会委员。曾主持多项美国NIH U54、R01和DoD研究项目。
PUBLICATIONS
1. Cui Z, Huang F, Fang K, Yan J, Zhang Y, Kang DD, Zhou Y, Zhao Y, Everitt JI, Hankey W, Armstrong AJ, Huang J, Wang H, Jin VX, Dong Y* and Wang Q*. SCORT-Cas13d nanotherapy precisely targets the ‘undruggable’ transcription factor HoxB13 in metastatic prostate cancer in vivo. Advanced Science, 2025 May 11:e2417605. doi: 10.1002/advs.202417605. Online ahead of print. (*Corresponding authors)
2. Huang F, Li K, Shevach JW and Wang Q. Emerging Therapies to Overcome Antiandrogen Resistance and Beyond in Lethal Prostate Cancer (invited review article). Journal of the National Cancer Center, 2025, https://doi.org/10.1016/j.jncc.2025.04.004.
3. Cui Z, Liu T, Bacon R, Zhao Y, Everitt JI, Yan J, Chen L, Wang H, Dong Y*, Jin VX*, Liu SL*, and Wang Q*. Single-dose cathepsin L CRISPR nanotherapy mitigates PASC-like lung damage in hamsters. Nano Research, 2025, https://doi.org/10.26599/NR.2025.94907695 (*Corresponding authors)
4. Zhou BR, Feng H, Huang F, Zhu I, Shi D, Zaret KS, Landsman D, Wang Q, and Bai Y. Structural insights for the cooperative nucleosome recognition and chromatin opening by FoxA1 and GATA4. Molecular Cell, 2024 Aug 22;84(16):3061-3079.e10. doi: 10.1016/j.molcel.2024.07.016.
5. Cui Z, Zeng C, Huang F, Yuan F, Yan J, Zhao Y, Zhou Y, Hankey W, Jin VX, Huang J, Staats HF, Everitt JI, Sempowski GD, Wang H, Dong Y*, Liu SL* and Wang Q*. Cas13d knockdown of lung protease Ctsl prevents and treats lethal SARS-CoV-2 infection. Nature Chemical Biology, 2022 Oct;18(10):1056-1064. doi: 10.1038/s41589-022-01094-4. (* Corresponding authors).
6. Li T, Liu Q, Chen Z, Fang K, Huang F, Fu X, Wang Q*, and Jin VX*. Dynamic nucleosome landscape elicits a novel noncanonical GATA2 pioneer model. Nature Communications, 2022 Jun 7;13(1):3145. doi: 10.1038/s41467-022-30960-x. (* Corresponding authors)
7. Chen Z*, Hankey W, Zhao Y, Groth J, Wang H, Huang J, Roeder RG, and Wang Q*. Transcriptional recycling assays identify PAF1 as a driver of RNA Pol II recycling. Nature Communications, 2021 Nov 3;12(1):6318. doi: 10.1038/s41467-021-26604-1. (* Corresponding authors)
8. Huang F, Chen H, Zhu X, Gong T, Li X, Hankey W, Ding D, Wang H, Chen Z*, Wang Q*, and Liu Z*. The oncogenic function of androgen receptor in esophageal squamous cell carcinoma is directed by GATA3. Cell Research, 31:362-365, 2021. doi: 10.1038/s41422-020-00428-y. (* Corresponding authors).
9. Yuan F, Hankey W, Wu D, Wang H, Somarelli J, Armstrong AJ, Huang J, Chen Z, Wang Q. Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic Acids Research, 47: 10104-10114, 2019
10. Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, Cheng X, Antonarakis ES, Wang QE, Liu Z, Huang THM, Jin VX, Clinton SK, Luo J*, Huang J*, Wang Q*. Diverse AR-V7 cistromes in castration-resistant prostate cancer growth are governed by HoxB13. Proc Natl Acad Sci USA, 115: 6810-6815, 2018. (* Corresponding authors).
11. Chen Z*, Lan X, Wu D, Sunkel B, Ye Z, Huang J, Liu Z, Clinton SK, Jin VX and Wang Q*. Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. Nature Communications, 6: 8323, 2015 (* Corresponding authors).
12. Chen K, Chen Z, Wu D, Zhang L, Lin X, Su J, Rodriguez B, Xi Y, Xia Z, Chen X, Shi X, Wang Q* and Li W*. Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes. Nature Genetics, 47: 1149-1157, 2015 (* Corresponding authors).
13. Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, Wang L, Sunkel B, Grenade C, Chen J, Zynger DL, Yan PS, Huang, J, Nephew KP, Huang THM, Lin S, Clinton SK, Li W, Jin VX and Wang Q. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer, EMBO Journal, 34: 502-516, 2015.
14. Wu D, Sunkel B, Chen Z, Li Q, Cassandra G, Ye Z, Ke J, Chen H, Nephew KP, Huang THM, Liu Z, Jin VX and Wang Q. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Research, 42: 3607-3622, 2014. (NAR Breakthrough Article).
15. Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, and Wang Q. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO Journal, 30:2405-2419, 2011.
16. Wang Q*^, Li, W^, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Wu T, Lupien M, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS*, and Brown M*. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell, 138:245-256, 2009. (*Corresponding authors, ^ First authors) (Cell Featured Article)
正在更新中...
您现在的位置：